Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Friday

Apellis Pharmaceuticals (NASDAQ:APLS) is projected to announce its earnings results before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $197.92 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $26.99 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 12 month low of $24.34 and a 12 month high of $71.90. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -13.29 and a beta of 0.96. The firm’s 50-day moving average is $30.34 and its 200 day moving average is $31.70.

Wall Street Analysts Forecast Growth

APLS has been the topic of a number of analyst reports. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price on the stock. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Bank of America decreased their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, January 29th. Finally, Robert W. Baird reduced their price target on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $46.71.

Insider Activity

In other news, CFO Timothy Eugene Sullivan sold 2,170 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the transaction, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at approximately $2,528,470. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Caroline Baumal sold 2,816 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now owns 55,560 shares of the company’s stock, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,365 shares of company stock worth $1,810,479. Corporate insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).